malaria consortium
malaria consortium Company Information
Company Number
04785712
Website
www.malariaconsortium.orgRegistered Address
the green house, cambridge heath road, london, E2 9DA
Industry
Other human health activities
Telephone
-
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
-0%
malaria consortium Estimated Valuation
Pomanda estimates the enterprise value of MALARIA CONSORTIUM at £102m based on a Turnover of £100.7m and 1.01x industry multiple (adjusted for size and gross margin).
malaria consortium Estimated Valuation
Pomanda estimates the enterprise value of MALARIA CONSORTIUM at £5.1m based on an EBITDA of £584.2k and a 8.75x industry multiple (adjusted for size and gross margin).
malaria consortium Estimated Valuation
Pomanda estimates the enterprise value of MALARIA CONSORTIUM at £40.6m based on Net Assets of £16.8m and 2.42x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Malaria Consortium Overview
Malaria Consortium is a live company located in london, E2 9DA with a Companies House number of 04785712. It operates in the other human health activities sector, SIC Code 86900. Founded in June 2003, it's largest shareholder is unknown. Malaria Consortium is a mature, mega sized company, Pomanda has estimated its turnover at £100.7m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Malaria Consortium Health Check
Pomanda's financial health check has awarded Malaria Consortium a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 3 areas for improvement. Company Health Check FAQs
5 Strong
2 Regular
3 Weak
Size
annual sales of £100.7m, make it larger than the average company (£725.1k)
£100.7m - Malaria Consortium
£725.1k - Industry AVG
Growth
3 year (CAGR) sales growth of 12%, show it is growing at a faster rate (5.3%)
12% - Malaria Consortium
5.3% - Industry AVG
Production
with a gross margin of 35.8%, this company has a comparable cost of product (35.8%)
35.8% - Malaria Consortium
35.8% - Industry AVG
Profitability
an operating margin of 0.5% make it less profitable than the average company (6%)
0.5% - Malaria Consortium
6% - Industry AVG
Employees
with 641 employees, this is above the industry average (19)
641 - Malaria Consortium
19 - Industry AVG
Pay Structure
on an average salary of £25.6k, the company has an equivalent pay structure (£24.6k)
£25.6k - Malaria Consortium
£24.6k - Industry AVG
Efficiency
resulting in sales per employee of £157.1k, this is more efficient (£43.3k)
£157.1k - Malaria Consortium
£43.3k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Malaria Consortium
- - Industry AVG
Creditor Days
its suppliers are paid after 76 days, this is slower than average (18 days)
76 days - Malaria Consortium
18 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Malaria Consortium
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 56 weeks, this is less cash available to meet short term requirements (140 weeks)
56 weeks - Malaria Consortium
140 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 91.2%, this is a higher level of debt than the average (21.8%)
91.2% - Malaria Consortium
21.8% - Industry AVG
MALARIA CONSORTIUM financials
Malaria Consortium's latest turnover from March 2023 is £100.7 million and the company has net assets of £16.8 million. According to their latest financial statements, Malaria Consortium has 641 employees and maintains cash reserves of £186.7 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 100,705,000 | 84,419,000 | 67,864,000 | 70,963,000 | 55,026,000 | 63,056,000 | 55,031,000 | 40,853,000 | 58,298,000 | 54,535 | 31,222,204 | 30,369,400 | 24,649,927 | 19,033,028 |
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | ||||||||||||||
| Admin Expenses | ||||||||||||||
| Operating Profit | ||||||||||||||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-Tax Profit | 5,987,000 | 4,663,000 | 1,042,000 | 26,841,000 | 18,586,000 | 16,906,000 | 4,191,000 | -336,000 | 1,489,000 | -568 | 488,262 | 330,419 | 131,159 | -831,335 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 5,987,000 | 4,663,000 | 1,042,000 | 26,841,000 | 18,586,000 | 16,906,000 | 4,191,000 | -336,000 | 1,489,000 | -568 | 488,262 | 330,419 | 131,159 | -831,335 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 5,987,000 | 4,663,000 | 1,042,000 | 26,841,000 | 18,586,000 | 16,906,000 | 4,191,000 | -336,000 | 1,489,000 | -568 | 488,262 | 330,419 | 131,159 | -831,335 |
| Employee Costs | 16,432,000 | 12,555,000 | 14,211,000 | 12,672,000 | 9,914,000 | 8,567,000 | 9,294,000 | 9,922,000 | 8,414,000 | 7,324 | 5,917,168 | 5,632,972 | 5,454,102 | 4,779,558 |
| Number Of Employees | 641 | 534 | 607 | 552 | 424 | 399 | 395 | 398 | 350 | 311 | 299 | 290 | 324 | 229 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 494,000 | 542,000 | 568,000 | 517,000 | 566,000 | 556,000 | 539,000 | 580,000 | 600,000 | 602 | 649,141 | 711,683 | 945,465 | 622,596 |
| Intangible Assets | 0 | 1,000 | 2,000 | 3,000 | 5,000 | 4,000 | 9,000 | 19,000 | 21,000 | 33 | 27,224 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 494,000 | 543,000 | 570,000 | 520,000 | 571,000 | 560,000 | 548,000 | 599,000 | 621,000 | 635 | 676,365 | 711,684 | 945,466 | 622,597 |
| Stock & work in progress | 0 | 0 | 2,000 | 0 | 0 | 198,000 | 91,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,425 | 0 | 7,109,653 | 3,888,588 | 3,229,401 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,368,987 | 46,837 | 28,790 | 0 |
| Misc Debtors | 2,823,000 | 1,239,000 | 3,482,000 | 5,377,000 | 6,634,000 | 4,893,000 | 7,968,000 | 5,927,000 | 8,048,000 | 0 | 998,515 | 1,330,618 | 1,018,134 | 1,297,780 |
| Cash | 186,747,000 | 135,941,000 | 80,859,000 | 76,584,000 | 43,673,000 | 27,062,000 | 24,378,000 | 7,996,000 | 12,766,000 | 11,424 | 6,251,401 | 7,903,974 | 10,775,414 | 10,631,050 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,517,272 | 0 | 0 | 0 |
| total current assets | 189,570,000 | 137,180,000 | 84,343,000 | 81,961,000 | 50,307,000 | 32,153,000 | 32,437,000 | 13,923,000 | 20,814,000 | 14,849 | 13,136,175 | 16,391,082 | 15,710,926 | 15,158,231 |
| total assets | 190,064,000 | 137,723,000 | 84,913,000 | 82,481,000 | 50,878,000 | 32,713,000 | 32,985,000 | 14,522,000 | 21,435,000 | 15,484 | 13,812,540 | 17,102,766 | 16,656,392 | 15,780,828 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 13,577,000 | 4,912,000 | 948,000 | 1,008,000 | 124,000 | 4,889,000 | 715,000 | 779,000 | 837,000 | 10,355 | 464,624 | 406,016 | 598,702 | 328,802 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 157,081,000 | 119,382,000 | 75,595,000 | 7,625,000 | 4,383,000 | 0 | 21,243,000 | 6,875,000 | 13,689,000 | 0 | 7,335,534 | 11,279,158 | 11,315,280 | 10,840,775 |
| total current liabilities | 170,658,000 | 124,294,000 | 76,543,000 | 8,633,000 | 4,507,000 | 4,889,000 | 21,958,000 | 7,654,000 | 14,526,000 | 10,355 | 7,800,158 | 11,685,174 | 11,913,982 | 11,169,577 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 2,640,000 | 2,650,000 | 2,254,000 | 1,175,000 | 542,000 | 581,000 | 690,000 | 722,000 | 427,000 | 136 | 451,291 | 344,763 | 0 | 0 |
| total long term liabilities | 2,640,000 | 2,650,000 | 2,254,000 | 1,175,000 | 542,000 | 581,000 | 690,000 | 722,000 | 427,000 | 136 | 451,291 | 344,763 | 0 | 0 |
| total liabilities | 173,298,000 | 126,944,000 | 78,797,000 | 9,808,000 | 5,049,000 | 5,470,000 | 22,648,000 | 8,376,000 | 14,953,000 | 10,491 | 8,251,449 | 12,029,937 | 11,913,982 | 11,169,577 |
| net assets | 16,766,000 | 10,779,000 | 6,116,000 | 72,673,000 | 45,829,000 | 27,243,000 | 10,337,000 | 6,146,000 | 6,482,000 | 4,993 | 5,561,091 | 5,072,829 | 4,742,410 | 4,611,251 |
| total shareholders funds | 16,766,000 | 10,779,000 | 6,116,000 | 72,673,000 | 45,829,000 | 27,243,000 | 10,337,000 | 6,146,000 | 6,482,000 | 4,993 | 5,561,091 | 5,072,829 | 4,742,410 | 4,611,251 |
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | ||||||||||||||
| Depreciation | 49,000 | 51,000 | 28,000 | 45,000 | 56,000 | 769,000 | 110,000 | 121,000 | 51,000 | 90,874 | 188,809 | 243,727 | 212,050 | 210,492 |
| Amortisation | 1,000 | 0 | 0 | 2,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock | 0 | -2,000 | 2,000 | 0 | -198,000 | 107,000 | 91,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 1,584,000 | -2,243,000 | -1,895,000 | -1,257,000 | 1,741,000 | -3,075,000 | 2,041,000 | -2,121,000 | 8,044,575 | -5,364,077 | -3,119,606 | 3,551,596 | 408,331 | 4,527,181 |
| Creditors | 8,665,000 | 3,964,000 | -60,000 | 884,000 | -4,765,000 | 4,174,000 | -64,000 | -58,000 | 826,645 | -454,269 | 58,608 | -192,686 | 269,900 | 328,802 |
| Accruals and Deferred Income | 37,699,000 | 43,787,000 | 67,970,000 | 3,242,000 | 4,383,000 | -21,243,000 | 14,368,000 | -6,814,000 | 13,689,000 | -7,335,534 | -3,943,624 | -36,122 | 474,505 | 10,840,775 |
| Deferred Taxes & Provisions | -10,000 | 396,000 | 1,079,000 | 633,000 | -39,000 | -109,000 | -32,000 | 295,000 | 426,864 | -451,155 | 106,528 | 344,763 | 0 | 0 |
| Cash flow from operations | ||||||||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | -68,000 | -116,000 | -86,000 | 72 | -155,416 | -29,069 | -540,129 | -432,741 |
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 1 |
| cash flow from investments | 0 | 0 | 0 | 0 | 0 | 0 | -68,000 | -116,000 | -86,000 | 72 | -155,415 | -29,069 | -540,129 | -432,742 |
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from financing | 0 | 0 | -67,599,000 | 3,000 | 0 | 0 | 0 | 0 | 4,988,007 | -5,555,530 | 0 | 0 | 0 | 5,442,586 |
| cash and cash equivalents | ||||||||||||||
| cash | 50,806,000 | 55,082,000 | 4,275,000 | 32,911,000 | 16,611,000 | 2,684,000 | 16,382,000 | -4,770,000 | 12,754,576 | -6,239,977 | -1,652,573 | -2,871,440 | 144,364 | 10,631,050 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 50,806,000 | 55,082,000 | 4,275,000 | 32,911,000 | 16,611,000 | 2,684,000 | 16,382,000 | -4,770,000 | 12,754,576 | -6,239,977 | -1,652,573 | -2,871,440 | 144,364 | 10,631,050 |
malaria consortium Credit Report and Business Information
Malaria Consortium Competitor Analysis
Perform a competitor analysis for malaria consortium by selecting its closest rivals and benchmarking them against 12 key performance metrics.
malaria consortium Ownership
MALARIA CONSORTIUM group structure
Malaria Consortium has no subsidiary companies.
Ultimate parent company
MALARIA CONSORTIUM
04785712
malaria consortium directors
Malaria Consortium currently has 11 directors. The longest serving directors include Prof Jayne Webster (Feb 2019) and Mr Ian Boulton (Mar 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Prof Jayne Webster | England | 61 years | Feb 2019 | - | Director |
| Mr Ian Boulton | England | 71 years | Mar 2020 | - | Director |
| Mr Ian Boulton | England | 71 years | Mar 2020 | - | Director |
| Miss Sherifatu Adigun | England | 43 years | Nov 2020 | - | Director |
| Ms Sarah De Tournemire | England | 54 years | Nov 2020 | - | Director |
| Professor Oumar Gaye | England | 72 years | Sep 2021 | - | Director |
| Ms Dawa Dem | England | 40 years | Sep 2021 | - | Director |
| Mr William Godfrey | 76 years | Mar 2022 | - | Director | |
| Ms Jane Edmondson | England | 63 years | Mar 2022 | - | Director |
| Professor Wilfred Mbacham | England | 60 years | Jul 2023 | - | Director |
P&L
March 2023turnover
100.7m
+19%
operating profit
534.2k
0%
gross margin
35.9%
+0.57%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
16.8m
+0.56%
total assets
190.1m
+0.38%
cash
186.7m
+0.37%
net assets
Total assets minus all liabilities
malaria consortium company details
company number
04785712
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
incorporation date
June 2003
age
21
accounts
Group
ultimate parent company
previous names
N/A
incorporated
UK
address
the green house, cambridge heath road, london, E2 9DA
last accounts submitted
March 2023
malaria consortium Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to malaria consortium. Currently there are 1 open charges and 0 have been satisfied in the past.
malaria consortium Companies House Filings - See Documents
| date | description | view/download |
|---|
